Accès ouvert
2026
article
OpenAlex
Rena Emond, Jeffrey West, Vince Kornél Grolmusz, Patrick A. Cosgrove et autres
Chemotherapy remains a commonly used and important treatment option for metastatic breast cancer. A majority of Estrogen Receptor-positive (ER + ) metastatic breast cancer patients ultimately develop resistance to chemotherapy, resulting in disease progression. We hypothesized that an "evolutionary double-bind", where adapting …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Isaac Bishara, Patrick A. Cosgrove, Sumana Majumdar, Colt A. Egelston et autres
Low-grade serous ovarian carcinoma (LGSOC) is a rare, treatment-resistant subtype of ovarian cancer characterized by peritoneal spread. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) delivers chemotherapy directly into the abdomen during serial laparoscopic surgeries, enabling repeated sampling of tumors for longitudinal analysis. Using single-nuclei …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jason I. Griffiths, Feng Chi, Elena Farmaki, Eric F. Medina et autres
Abstract In early-stage estrogen receptor-positive (ER + ) breast cancer, resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) often involve a shift away from estrogen-driven proliferation. The nature and source of compensatory growth signals driving cancer proliferation remain unknown but represent …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Jiyeon Park, Frederick R. Adler, Aritro Nath, Jason I. Griffiths et autres
Abstract Advanced estrogen receptor positive (ER+) breast cancers are typically treated with endocrine therapy (ET) plus cell cycle inhibitors (CCI); however, nearly 20% of these cancers recur due to treatment resistance. Our previous study of tumor intrinsic properties during CCI plus ET …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Isaac Bishara, Xuan Liu, Patrick A. Cosgrove, Jasmine R. McQuerry et autres
End stage breast cancer often presents with oligometastatic tumors and lacks effective treatment options. Previous studies leveraged post-mortem tissue procurement (also called rapid autopsy) programs to collect tumors shortly after death for profiling by bulk whole exome sequencing (WES). This has revealed …
us, au
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jason I. Griffiths, Patrick A. Cosgrove, Eric F. Medina, Aritro Nath et autres
Immune evasion by cancer cells involves reshaping the tumor microenvironment (TME) via communication with non-malignant cells. However, resistance-promoting interactions during treatment remain lesser known. Here we examine the composition, communication, and phenotypes of tumor-associated cells in serial biopsies from stage II and …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Patrick A. Cosgrove, Andrea H. Bild, Thanh H. Dellinger, Behnam Badie et autres
Tumor heterogeneity is a significant factor influencing cancer treatment effectiveness and can arise from genetic, epigenetic, and phenotypic variations among cancer cells. Understanding how tumor heterogeneity impacts tumor evolution and therapy response can lead to more effective treatments and improved patient outcomes. …
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Rena Emond, Jeffrey West, Vince Kornél Grolmusz, Patrick A. Cosgrove et autres
Chemotherapy remains a commonly used and important treatment option for metastatic breast cancer. A majority of ER+ metastatic breast cancer patients ultimately develop resistance to chemotherapy, resulting in disease progression. We hypothesized that an "evolutionary double-bind", where treatment with one drug improves …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Isaac Bishara, Xuan Liu, Jason I. Griffiths, Jiayi Liu et autres
Abstract Metastatic breast cancers show variable clinical responses due to inherent heterogeneity, both within tumors and among patients. Studies mainly examine molecular diversity across different patients' tumors and genetic variance within a single tumor. Yet, the variability among multiple tumors or metastases …
us, au
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Eric F. Medina, Patrick A. Cosgrove, Εleni Farmaki, Vince Kornél Grolmusz et autres
Abstract Breast cancer is the most common malignancy in women and estrogen receptor positive (ER+) breast cancers represent nearly 75% of all breast tumors. Everolimus, an mTORC1 inhibitor, in combination with exemestane has been approved for patients with metastatic ER+ breast cancer. …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Elena Farmaki, Aritro Nath, Rena Emond, Kimya L Karimi et autres
The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness. We developed ER+ BC cell lines, …
us
(code pays fourni par la source)
Accès ouvert
2023
peer-review
OpenAlex
Elena Farmaki, Aritro Nath, Rena Emond, Kimya L Karimi et autres
Breast cancer is one of the most frequently diagnosed cancers globally, particularly among women. The most common type of breast cancer expresses a receptor for the hormone estrogen. Many treatments block the activity of estrogen and therefore slow or block the development …
us
(code pays fourni par la source)